Gemcabene is primarily investigated for its potential therapeutic applications in managing lipid disorders. It functions by modulating lipid metabolism, making it a candidate for treating conditions like hypercholesterolemia and hypertriglyceridemia. The compound works by enhancing the breakdown and clearance of lipids from the bloodstream, thereby reducing the risk of cardiovascular diseases. Clinical studies have explored its efficacy in lowering LDL cholesterol and triglycerides while increasing HDL cholesterol levels. Additionally, gemcabene has shown promise in addressing non-alcoholic fatty liver disease (NAFLD) by reducing liver fat accumulation and improving liver function. Its mechanism of action involves targeting key enzymes and pathways involved in lipid synthesis and metabolism, offering a potential alternative for patients who do not respond adequately to conventional lipid-lowering therapies.